A genetically engineered chimeric vaccine against porcine circovirus type 2 (PCV2) improves clinical, pathological and virological outcomes in postweaning multisystemic wasting syndrome affected farms

J. Segalés, A. Urniza, A. Alegre, T. Bru, E. Crisci, M. Nofrarías, S. López-Soria, M. Balasch, M. Sibila, Z. Xu, H. J. Chu, L. Fraile, J. Plana-Duran

Research output: Contribution to journalArticleResearchpeer-review

61 Citations (Scopus)

Abstract

The present study describes the effects of a commercially available genetically engineered chimeric vaccine against porcine circovirus type 2 (PCV2) on clinical, pathological and virological features in three multi-site farms suffering from postweaning multisystemic wasting syndrome (PMWS). The vaccine product was able to reduce clinical signs, PCV2 viral load in lymphoid organs and/or sera, and overall mortality in nurseries and fattening units. This is the first time in which is shown that a PCV2 vaccine is able to decrease specifically PMWS-associated mortality. Another novelty of this study is the assessment of PMWS-like histological lesions in a large number of vaccinated and non-vaccinated pigs under field conditions. © 2009 Elsevier Ltd. All rights reserved.
Original languageEnglish
Pages (from-to)7313-7321
JournalVaccine
Volume27
Issue number52
DOIs
Publication statusPublished - 9 Dec 2009

Keywords

  • Porcine circovirus type 2 (PCV2)
  • Postweaning multisystemic wasting syndrome (PMWS)
  • Vaccine

Fingerprint Dive into the research topics of 'A genetically engineered chimeric vaccine against porcine circovirus type 2 (PCV2) improves clinical, pathological and virological outcomes in postweaning multisystemic wasting syndrome affected farms'. Together they form a unique fingerprint.

Cite this